基于logistic回归分析探究分化型甲状腺癌全切术后3.70 GBq 131I治疗效果的影响因素

doi:10.20047/j.issn1673-7210.2023.20.28

Abstract
Figure/Table
References (29)
Related Citation (15)

Download: PDF (687 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the factors influencing the therapeutic effect of 3.70 GBq 131I after total resection of differentiated thyroid carcinoma. Methods A total of 151 patients with differentiated thyroid carcinoma who received initial 131I treatment (dose 3.70 GBq) at the Department of Nuclear Medicine of Qingyuan People’s Hospital, Guangdong Province from July 2018 to May 2022 were collected. According to the results 6-12 months after discharge, they were divided into excellent response (ER) group (70 cases) and non-ER (NER) group (81 cases). Gender, age, pathological type, T stage, N stage, positive rate of static thyroid imaging, thyroid stimulating hormone (TSH), postoperative interval, 24 h radioactive iodine uptake (24h-RAIU), and serum stimulating thyroglobulin (sTg) were collected and compared between the two groups. Multivariate logistic regression model was used to analyze the factors affecting the effect of 3.70 GBq 131I treatment after total resection of differentiated thyroid carcinoma. Results The static thyroid imaging positive rate and sTg in NER group were higher than those in ER group, and the postoperative interval was shorter than that in ER group (P＜0.05). The results of multivariate analysis showed that thyroid static imaging status (OR=3.470, 95%CI: 1.559-7.725), postoperative interval (OR=0.667, 95%CI: 0.549-0.811), sTg (OR=1.092, 95%CI: 1.046-1.141) were the independent influencing factors of 3.70 GBq 131I treatment after total resection of differentiated thyroid carcinoma (P＜0.05). Conclusion Static thyroid imaging, postoperative interval, and sTg level are related to the effect of 3.70 GBq 131I treatment in patients with differentiated thyroid carcinoma after total resection. Attention should be paid to patients with abnormal three indicators.

Key words： Differentiated thyroid carcinoma 131I treatment Logistic regression analysis Influencing factor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Ziyan　YANG Shijian▲　LI Guangming　XU Miaoyu

Cite this article:

WANG Ziyan　YANG Shijian▲　LI Guangming　XU Miaoyu. Analysis of influencing factors of 3.70 GBq 131I treatment after total rese-ction of differentiated thyroid carcinoma based on logistic regression ana- lysis[J]. 中国医药导报, 2023, 20(20): 129-133.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.20.28 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I20/129

[1] ■zdo■an ■，Aksu A，Do■an E，et al. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma [J]. Ann Nucl Med，2021，35（2）：223-231.
[2] 齐萌芳，田甜，黄蕤.不同年龄儿童及青少年分化型甲状腺癌患者的临床病理学特征与131I治疗分析[J].中国癌症杂志，2022，32（5）：404-409.
[3] Vallejo JA. Role of 131I in low-risk differentiated thyroid cancer [J]. Rev Esp Med Nucl Imagen Mol（Engl Ed），2023， 42（1）：33-37.
[4] 刘娇，程兵，常伟，等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志，2016，40（6）：419-423.
[5] 何健，陈倩，李攀，等.不同清甲剂量131I对中低危分化型甲状腺癌患者治疗后临床反应和免疫功能的影响[J].标记免疫分析与临床，2022，29（4）：613-617.
[6] 中华医学会核医学分会.131I治疗分化型甲状腺癌指南（2021版）[J].中华核医学与分子影像杂志，2021，41（4）：218-241.
[7] Lan W，Gege Z，Ningning L，et al. Negative remnant 99mTc- pertechnetate uptake predicts excellent response to radioactive iodine therapy in low- to intermediate-risk differentiated thyroid cancer patients who have undergone total thyroidectomy [J]. Ann Nucl Med，2019，33（2）：112-118.
[8] 宋娟娟，慕转转，鲁涛，等.131I辅助治疗对BRAFV600E突变型非远处转移性甲状腺乳头状癌患者疗效的初步探讨[J].中华核医学与分子影像杂志，2021，41（4）：212- 217.
[9] Haugen BR，Alexander EK，Bible KC，et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer：The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer [J]. Thyroid，2016，26（1）：1-133.
[10] 袁小兵，陈慰慰，刘小莉，等.不同手术入路甲状腺根治术治疗分化型甲状腺癌患者的安全性及预后观察[J].中国医药导报，2022，19（17）：131-134，162.
[11] 房居高.分化型甲状腺癌诊治中的热点及争议问题[J].中华医学杂志，2022，102（48）：3801-3805.
[12] 董晨花，江涛，宋军.分化型甲状腺癌腺叶切除研究综述[J].中国医药科学，2021，11（13）：40-42，46.
[13] 邓俊华，曾田雨，秦永章，等.分化型甲状腺癌术后碘-131清除残余甲状腺组织安全性分析[J].中国当代医药，2022，29（26）：35-39.
[14] 赵玮，史良平，程义壮.131I清甲治疗前sTg水平与DTC术后清甲治疗疗效的关系[J].分子诊断与治疗杂志，2022，14（8）：1300-1303.
[15] 李浩宇，刘超，侯飞，等.分化型甲状腺癌患者131I治疗前停服左旋甲状腺激素后血脂、血压与甲状腺功能的相关性分析[J].中国医药科学，2021，11（4）：1-4.
[16] James DL，Ryané J，Davey MG，et al. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer：A Systematic Review and Meta-analysis [J]. JAMA Otolaryngol Head Neck Surg，2021，147（6）：544-552.
[17] Gao H，Huang J，Dai Q，et al. Radioiodine（131I）treatment decision-making for low-and intermediate-risk differentiated thyroid cancer [J]. Arch Endocrinol Metab，2023，67（2）：197-205.
[18] 赵凯，崔宁，张虎，等.血脂及血清IL-6、TSH检测与分化型甲状腺癌患者临床病理特征的关系[J].中华内分泌外科杂志，2022，16（4）：441-446.
[19] Wang C，Diao H，Ren P，et al. Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma [J]. Front Oncol，2018，8：640.
[20] Zhao T，Liang J，Guo Z，et al. In Patients With Low- to Intermediate-Risk Thyroid Cancer，a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy [J]. Clin Nucl Med，2016，41（6）：454- 458.
[21] 武鸿文，梅艳，王乔，等.血清MIP-1α、S-TK1对于甲状腺癌术后放射性131I治疗效果评估的临床价值[J].中国癌症杂志，2021，31（11）：1088-1095.
[22] Kim HK，Yoon JH，Cho JS，et al. The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer [J]. Korean J Intern Med，2020，35（5）：1164-1172.
[23] Suman P，Wang CH，Abadin SS，et al. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA [J]. Endocr Pract，2016，22（7）： 822-831.
[24] Buckalew AR，Wang J，Murr AS，et al. Evaluation of potential sodium-iodide symporter（NIS）inhibitors using a secondary Fischer rat thyroid follicular cell（FRTL-5）radioactive iodide uptake（RAIU）assay [J]. Arch Toxicol，2020，94（3）：873-885.
[25] Xiao L，Wang Y，Huang R，et al. Stimulated serum thyroglobulin but not RAIU level is a prognostic factor for ablation efficacy with a 3.7GBq（100mCi）fixed 131I dose in patients with differentiated thyroid cancer [J]. Hell J Nucl Med，2021，24（1）：53-59.
[26] Pabst KM，Seifert R，Hirmas N，et al. Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancer [J]. Endocr Connect，2023，12（2）：e220312.
[27] 巴雅，祖拉亚提·库尔班，娜姿·依力哈木，等.血清Tg和TgAb对分化型甲状腺癌切除术后131I治疗患者预后的预测价值[J].疑难病杂志，2023，22（2）：144-148， 154.
[28] 钟凯翔，张金山，张语微，等.99mTcO4-功能显像联合彩超检查对甲状腺结节性质的诊断评价——与病理结果的对照分析[J].实用医学杂志，2020，36（1）：103-107.
[29] Eloteify LM，Algizawy SM，Abdelnaim A，et al. The prognostic value of post thyroidectomy Tc-99m pertechnetate thyroid scan in patients with differentiated thyroid cancer [J]. Nucl Med Commun，2023，44（1）：38-43.